Literature DB >> 22704959

Brody syndrome: a clinically heterogeneous entity distinct from Brody disease: a review of literature and a cross-sectional clinical study in 17 patients.

N C Voermans1, A E Laan, A Oosterhof, T H van Kuppevelt, G Drost, M Lammens, E J Kamsteeg, C Scotton, F Gualandi, V Guglielmi, L van den Heuvel, G Vattemi, B G van Engelen.   

Abstract

Brody disease is a rare inherited myopathy due to reduced sarcoplasmic reticulum Ca(2+) ATPase (SERCA)1 activity caused by mutations in ATP2A1, which causes delayed muscle relaxation and silent cramps. So far the disease has mostly been diagnosed by measurement of SERCA1 activity. Since mutation analysis became more widely available, it has appeared that not all patients with reduced SERCA1 activity indeed have ATP2A1 mutations, and a distinction between Brody disease (with ATP2A1 mutations) and Brody syndrome (without ATP2A1 mutations) was proposed. We aim to compare the clinical features of patients with Brody disease and those with Brody syndrome and detect clinical features which help to distinguish between the two. In addition, we describe the Brody syndrome phenotype in more detail. We therefore performed a literature review on clinical features of both Brody disease and Brody syndrome and a cross-sectional clinical study consisting of questionnaires, physical examination, and a review of medical files in 17 Brody syndrome patients in our centre. The results showed that Brody disease presents with an onset in the 1st decade, a generalized pattern of muscle stiffness, delayed muscle relaxation after repetitive contraction on physical examination, and autosomal recessive inheritance. Patients with Brody syndrome more often report myalgia and experience a considerable impact on daily life. Future research should focus on the possible mechanisms of reduction of SERCA activity in Brody syndrome and other genetic causes, and on evaluation of treatment options.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22704959     DOI: 10.1016/j.nmd.2012.03.012

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  11 in total

1.  Stromal interaction molecule 1 (STIM1) regulates sarcoplasmic/endoplasmic reticulum Ca²⁺-ATPase 1a (SERCA1a) in skeletal muscle.

Authors:  Keon Jin Lee; Changdo Hyun; Jin Seok Woo; Chang Sik Park; Do Han Kim; Eun Hui Lee
Journal:  Pflugers Arch       Date:  2014-05       Impact factor: 3.657

2.  Mitsugumin 53 attenuates the activity of sarcoplasmic reticulum Ca(2+)-ATPase 1a (SERCA1a) in skeletal muscle.

Authors:  Keon Jin Lee; Chang Sik Park; Jin Seok Woo; Do Han Kim; Jianjie Ma; Eun Hui Lee
Journal:  Biochem Biophys Res Commun       Date:  2012-10-24       Impact factor: 3.575

3.  Mice with RyR1 mutation (Y524S) undergo hypermetabolic response to simvastatin.

Authors:  Mark Knoblauch; Adan Dagnino-Acosta; Susan L Hamilton
Journal:  Skelet Muscle       Date:  2013-09-03       Impact factor: 4.912

4.  Exome analysis identifies Brody myopathy in a family diagnosed with malignant hyperthermia susceptibility.

Authors:  Nyamkhishig Sambuughin; Elena Zvaritch; Natasha Kraeva; Olga Sizova; Erica Sivak; Kelley Dickson; Margaret Weglinski; John Capacchione; Sheila Muldoon; Sheila Riazi; Susan Hamilton; Barbara Brandom; David H MacLennan
Journal:  Mol Genet Genomic Med       Date:  2014-06-06       Impact factor: 2.183

5.  Calcium homeostasis in myogenic differentiation factor 1 (MyoD)-transformed, virally-transduced, skin-derived equine myotubes.

Authors:  Marta Fernandez-Fuente; Cesare M Terracciano; Pilar Martin-Duque; Susan C Brown; Georges Vassaux; Richard J Piercy
Journal:  PLoS One       Date:  2014-08-22       Impact factor: 3.240

6.  Calpain 3 deficiency affects SERCA expression and function in the skeletal muscle.

Authors:  Ivan Toral-Ojeda; Garazi Aldanondo; Jaione Lasa-Elgarresta; Haizpea Lasa-Fernández; Roberto Fernández-Torrón; Adolfo López de Munain; Ainara Vallejo-Illarramendi
Journal:  Expert Rev Mol Med       Date:  2016-04-08       Impact factor: 5.600

7.  STIM2 regulates both intracellular Ca2+ distribution and Ca2+ movement in skeletal myotubes.

Authors:  Mi Ri Oh; Keon Jin Lee; Mei Huang; Jin Ock Kim; Do Han Kim; Chung-Hyun Cho; Eun Hui Lee
Journal:  Sci Rep       Date:  2017-12-20       Impact factor: 4.379

8.  Inhibition of ubiquitin proteasome system rescues the defective sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA1) protein causing Chianina cattle pseudomyotonia.

Authors:  Elisa Bianchini; Stefania Testoni; Arcangelo Gentile; Tito Calì; Denis Ottolini; Antonello Villa; Marisa Brini; Romeo Betto; Francesco Mascarello; Poul Nissen; Dorianna Sandonà; Roberta Sacchetto
Journal:  J Biol Chem       Date:  2014-10-06       Impact factor: 5.157

9.  Identification of a pathogenic mutation in ATP2A1 via in silico analysis of exome data for cryptic aberrant splice sites.

Authors:  Christine C Bruels; Chengcheng Li; Tonatiuh Mendoza; Jamillah Khan; Hemakumar M Reddy; Elicia A Estrella; Partha S Ghosh; Basil T Darras; Hart G W Lidov; Christina A Pacak; Louis M Kunkel; François Modave; Isabelle Draper; Peter B Kang
Journal:  Mol Genet Genomic Med       Date:  2019-01-28       Impact factor: 2.183

10.  Clinical, morphological and genetic characterization of Brody disease: an international study of 40 patients.

Authors:  Joery P Molenaar; Jamie I Verhoeven; Richard J Rodenburg; Erik J Kamsteeg; Corrie E Erasmus; Savine Vicart; Anthony Behin; Guillaume Bassez; Armelle Magot; Yann Péréon; Barbara W Brandom; Valeria Guglielmi; Gaetano Vattemi; Frédéric Chevessier; Jean Mathieu; Jérôme Franques; Karen Suetterlin; Michael G Hanna; Lucie Guyant-Marechal; Marc M Snoeck; Mark E Roberts; Thierry Kuntzer; Roberto Fernandez-Torron; Amaia Martínez-Arroyo; Juergen Seeger; Benno Kusters; Susan Treves; Baziel G van Engelen; Bruno Eymard; Nicol C Voermans; Damien Sternberg
Journal:  Brain       Date:  2020-02-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.